Synthetic Biologics Inc. [SYN] Is Still Undervalued at $0.37

Synthetic Biologics Inc. [SYN] stock is up 1.27 while the S&P 500 has fallen -0.08% on Friday, 12/04/20. While at the time of this article, SYN ATR is sitting at 0.02, with the beta value at 2.28. This stock’s volatility for the past week remained at 5.67%, while it was 7.45% for the past 30-day period. SYN has fallen $0.0 from the previous closing price of $0.37 on volume of 0.96 million shares.

On 24, November 2020, Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American. According to news published on Yahoo Finance, Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on November 23, 2020, the NYSE American LLC (“NYSE American”), the Company’s current listing exchange, notified the Company that it had been granted an extension until May 25, 2021 to regain compliance with certain continued listing standards as set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.

Analyst Birdseye View:

The most recent analyst activity for Synthetic Biologics Inc. [AMEX:SYN] stock was on May 06, 2016, when it was Reiterated with an Outperform rating from FBR Capital, which also lowered its 12-month price target on the stock from $10 to $9. Before that, on January 06, 2017, FBR & Co. Recapitulated an Outperform rating and elevated its amount target to $6. On February 26, 2016, FBR Capital Initiated an Outperform rating and boosted its price target on this stock to $10. On October 13, 2015, RBC Capital Mkts Initiated an Outperform rating and increased its price target to $8. On March 16, 2015, Maxim Group Downgrade a Hold rating and increased its price target to $3. On March 02, 2015, Maxim Group Reiterated a Buy rating and boosted its amount target on this stock to $3. On March 19, 2014, Maxim Group Reiterated a Buy rating and boosted its target amount on this stock from $3 to $6. On September 30, 2013, Maxim Group Initiated a Buy rating and amplified its amount target to $3.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.25 and a peak of $0.75. Right now, according to Wall Street analyst the average 12-month amount target is $1.38. At the most recent market close, shares of Synthetic Biologics Inc. [AMEX:SYN] were valued at $0.37.

FUNDAMENTAL ANALYSIS

The Principal structure of this organization shows its whole liability to whole principal at 4.79 and the whole liability to whole assets at 4.19. It shows enduring liability to the whole principal at 3.14 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.3602 points at 1st support level, the second support level is making up to 0.3504. But as of 1st resistance point, this stock is sitting at 0.3796 and at 0.3892 for 2nd resistance point.

Synthetic Biologics Inc. [SYN] reported its earnings at -$0.14 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.17/share signifying the difference of 0.03 and 17.60% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.18 calling estimates for -$0.16/share with the difference of -0.02 depicting the surprise of -12.50%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Synthetic Biologics Inc. [AMEX:SYN] is 2.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.85.